Tetra Bio-Pharma Engages LifeSci Advisors and LifeSci PR Tetra Bio-Pharma Engages LifeSci Advisors and LifeSci Public Relations as Strategic Partners
Integrated Corporate Communications, Public Relations and Investor Relations Program to Focus on Elevating Company’s Visibility Ahead of Multiple Key Milestones
ORLEANS, Ontario, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in drug discovery and development for cannabinoid-based therapeutics, announced today the company has engaged LifeSci Advisors LLC, a leading investor relations consultancy serving life science companies, and LifeSci Public Relations LLC, a corporate communications firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools. LifeSci will work to implement and execute a comprehensive investor relations and communications program that will include analyst and investor targeting/outreach, non-deal roadshows, corporate communications, media engagement, social media and Key Opinion Leader (KOL) events.
“We are delighted to engage LifeSci during this exciting time of growth for Tetra,” said Guy Chamberland, Ph.D., chief executive officer and chief scientific officer of Tetra Bio-Pharma. “With multiple value-creating milestones on the horizon, it is important for us to clearly communicate our overarching value proposition to investors and the industry as we achieve these key inflection points. We believe LifeSci and its robust and unique integrated platform is in the best position to help us do that.”
The agreement for the engagement of LifeSci Advisors commenced on August 6, 2019 for a term of 12 months. LifeSci Advisors will be paid fees of US$30,000 per month for its services, with an annual increase of 5% on such monthly fee.
Please visit LifeSci Advisors and LifeSci Public Relations for more information.
About Tetra Bio-Pharma:
Tetra Bio-Pharma Inc. (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com More information at: www.tetrabiopharma.com Source: Tetra Bio-Pharma.